A new proof-of-concept study by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) shows that changing only a single letter in the DNA code of selected genes in T cells may lead to improved cell therapy. The researchers, led by Benjamin Izar, a member of the HICCC, used novel CRISPR-dependent base editing to "supercharge" cell therapies, making them potentially more effective for more patients.
A recent study in Nature Biotechnology shows increasing grants for female biomedical researchers, yet younger women face fewer opportunities. Read to learn more.
Leadership from clinical stage artificial intelligence (AI)-powered drug discovery company Insilico Medicine ("Insilico") will attend the BIO International Convention in San Diego June 3-6 and present on key issues facing AI drug discovery.